Day: January 11, 2022

First Citizens BancShares, Inc. Announces Date of 2021 Fourth Quarter and Year End Financial Results, Earnings Call

First Citizens BancShares, Inc. Announces Date of 2021 Fourth Quarter and Year End Financial Results, Earnings Call

RALEIGH, N.C., Jan. 11, 2022 (GLOBE NEWSWIRE) — First Citizens BancShares, Inc. today announced that it will report its financial results for the fourth quarter and year ended December 31, 2021, before the U.S. financial markets open on Wednesday, January 26, 2022. In addition, First Citizens will host a conference call to discuss the company’s financial results on January 26, 2022, at 9 a.m. Eastern time. To access this call, dial: Domestic:   833-654-8257 International:   602-585-9869 Conference ID:    1049136 The earnings presentation and news release will be available on the company’s website at www.firstcitizens.com/investor-relations. After the conference call, you may access a replay of the call through February 10, 2022, by dialing 855-859-2056 (domestic) or 404-537-3406 (international) with conference ID 1049136. About...

Continue reading

USCB Financial Holdings, Inc. to Announce Fourth Quarter 2021 Results

USCB Financial Holdings, Inc. to Announce Fourth Quarter 2021 Results

MIAMI, Jan. 11, 2022 (GLOBE NEWSWIRE) — USCB FINANCIAL HOLDINGS, INC. (the “Company”) (NASDAQ: USCB) will report financial results for the quarter ended December 31, 2021 after the market closes on Thursday, January 27, 2022. A conference call to discuss quarterly results will also be held with President and Chief Executive Officer, Luis de la Aguilera, and Chief Financial Officer, Robert Anderson, details which are provided below. Live Conference Call and Audio Webcast Date: Friday, January 28, 2022Time: 9:00 a.m. Eastern TimeDial-in: (844) 221-2148 (toll free in the U.S. or Canada) or (929) 517-0937 (international)Conference ID: 4543356 A live audio webcast of the call will be available with the press release and slides on the investor relations page of the Company’s website at https://investors.uscenturybank.com/. Please...

Continue reading

Stryve Foods, Inc. Closes $35.0 Million in Private Offering to Support its Growth

Stryve Foods, Inc. Closes $35.0 Million in Private Offering to Support its Growth

PLANO, Texas, Jan. 11, 2022 (GLOBE NEWSWIRE) — Stryve Foods, Inc. (“Stryve” or “the Company”), (NASDAQ: SNAX), an emerging healthy snack and eating platform disrupting traditional consumer packaged goods (“CPG”) categories, and a leader in the air-dried meat snack industry in the United States, today announced the closing of its previously announced private placement of 2,496,934 shares of its Class A common stock (the “Common Stock”) and, in lieu of Common Stock, 7,797,184 pre-funded warrants to purchase shares of Common Stock at an exercise price of $0.0001 per share (the “Pre-Funded Warrants”), and 10,294,118 accompanying warrants (the “Warrants”) immediately exercisable to purchase shares of Common Stock for a period of five years at an exercise price of $3.60 per share, pursuant to a securities purchase agreement between the...

Continue reading

Seneca Resources Achieves Certification of its Appalachian Natural Gas Production under the Equitable Origin Standard

Seneca Resources Achieves Certification of its Appalachian Natural Gas Production under the Equitable Origin Standard

WILLIAMSVILLE, N.Y., Jan. 11, 2022 (GLOBE NEWSWIRE) — Today, Seneca Resources Company, LLC (Seneca), the Exploration and Production segment of National Fuel Gas Company (NYSE: NFG) (National Fuel or the Company), announced it has achieved certification of 100% of its Appalachian natural gas production, over 1 billion cubic feet of daily gross production, under Equitable Origin’s EO100™ Standard for Responsible Energy Development, a series of rigorous environmental, social, and governance (ESG) performance targets. As part of the certification process, a team of accredited auditors from Geosyntec, representing a variety of technical and social backgrounds, conducted an independent, third-party audit of Seneca’s Pennsylvania operations to assess its alignment to the five principles of the EO100™ Standard, including corporate governance...

Continue reading

U.S. Global Investors Announces Sustainably Robust Quarter, with Average AUM Up 100% from the Same Period Last Year and Net Income at $0.16 Per Share, up 23% Year-Over-Year

U.S. Global Investors Announces Sustainably Robust Quarter, with Average AUM Up 100% from the Same Period Last Year and Net Income at $0.16 Per Share, up 23% Year-Over-Year

U.S. Global Investors vs. Competition Source: U.S. Global Investors USLUX Outperformed Its Index Source: Bloomberg, U.S. Global Investors San Antonio, TX, Jan. 11, 2022 (GLOBE NEWSWIRE) — U.S. Global Investors, Inc. (NASDAQ: GROW) (the “Company”), a registered investment advisory firm with longstanding experience in global markets and specialized sectors from gold mining to cryptocurrencies, today is pleased to report financial results for the fiscal quarter ended September 30, 2021. For the three-month period, total operating revenues were $6.5 million, an increase of over 100% year-over-year (YoY). Net income for the quarter was $2.4 million, or $0.16 per share, an increase of 23% YoY. Average assets under management (AUM) for the three-month period ended September 30, 2021, were $4.0 billion, twice...

Continue reading

Qbox Joins Instaclustr, the Platform for Open Source Data Infrastructure

Qbox Joins Instaclustr, the Platform for Open Source Data Infrastructure

A leader in delivering OpenSearch and Elasticsearch as a hosted service, Qbox strengthens Instaclustr’s comprehensive offering around the distributed search and analytics technology FAYETTEVILLE, Ark., Jan. 11, 2022 (GLOBE NEWSWIRE) — Qbox, which provides hosted OpenSearch and Elasticsearch solutions and support, announced today that the company has joined Instaclustr, which helps organizations deliver applications at scale by operating and supporting their open source data infrastructure. With deep expertise delivering Elasticsearch and OpenSearch as a fully-hosted service, Qbox is a natural addition to Instaclustr for its strong technical acumen around mission-critical data solutions and its commitment to open source technology. For nearly a decade, Qbox has grown its impressive customer base – which includes data-intensive companies...

Continue reading

Highwoods to Release Fourth Quarter and Full Year 2021 Results Tuesday, February 8th      

Highwoods to Release Fourth Quarter and Full Year 2021 Results Tuesday, February 8th      

Conference Call Wednesday, February 9th, at 11:00 A.M. RALEIGH, N.C., Jan. 11, 2022 (GLOBE NEWSWIRE) —  Highwoods Properties, Inc. (NYSE:HIW) will release its fourth quarter and full year 2021 results on Tuesday, February 8th, after the market closes. A conference call will be held the next day, Wednesday, February 9th, at 11:00 A.M. Eastern time. For US/Canada callers, dial (800) 756-3565. A live, listen-only webcast can be accessed through the Company’s website at www.highwoods.com under the “Investors” section.   A replay of the call will also be available on the Company’s website. Planned Dates for Financial Releases and Conference Calls in 2022 The Company has set the following dates for the release of its 2022 financial results. Quarterly financial releases will be distributed after the market closes and conference calls...

Continue reading

PROCEPT BioRobotics Corp. Announces Preliminary Fourth Quarter and Fiscal Year 2021 Revenue

PROCEPT BioRobotics Corp. Announces Preliminary Fourth Quarter and Fiscal Year 2021 Revenue

REDWOOD CITY, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) — PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported preliminary unaudited revenue for the fourth quarter and fiscal year ended December 31, 2021. Preliminary, Unaudited Revenue Highlights: Revenue for the fourth quarter of 2021 is expected to be in the range of $9.8 million to $10.1 million, compared to $3.2 million in the prior year period. Total U.S. revenue of $8.4 million to $8.7 million for the fourth quarter of 2021 U.S. system sales and rental revenue of approximately $5.0 million and U.S. handpieces and other consumables revenue of approximately $3.4 million for the fourth quarter of 2021 Total International revenue of approximately $1.4 million...

Continue reading

Minerva Surgical Reports Preliminary Fourth Quarter and Full Year 2021 Revenue

Minerva Surgical Reports Preliminary Fourth Quarter and Full Year 2021 Revenue

SANTA CLARA, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) — Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a medical device company that has established a broad product line of commercially available, minimally invasive medical devices that address the most common causes of abnormal uterine bleeding (AUB) as alternatives to hysterectomy, today reported preliminary unaudited fourth quarter and full year 2021 revenue expectations. Preliminary Fourth Quarter and Full Year 2021 Highlights: Fourth quarter 2021 revenues are expected to be in the range of $13.5M – $13.7M, compared with revenues of $13.6M in fourth quarter of 2020. Full year 2021 revenues are expected to be in the range of $52.0M – $52.2M, compared with reported revenues of $37.8M for full year 2020. Ended 2021 with over $40M in cash and...

Continue reading

<div>Aclaris Therapeutics Provides R&D Update</div>

Aclaris Therapeutics Provides R&D Update

WAYNE, Pa., Jan. 11, 2022 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today provides an update on the status of certain of its clinical programs and on its research and development (R&D) operations. Clinical Program Update: Zunsemetinib, an Investigational Oral MK2 Inhibitor Aclaris initiated study activities and began activating sites in December 2021 in the following two studies: ATI-450-RA-202: Phase 2b clinical trial of zunsemetinib in subjects with moderate to severe rheumatoid arthritis (RA). This is Aclaris’ second Phase 2 clinical trial of zunsemetinib in subjects with moderate to severe RA, and is primarily designed to assess the efficacy of multiple doses of zunsemetinib to...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.